Point72 Asset Management
RARE icon

Point72 Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Point72 Asset Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-58,800
Closed -$2.42M – 2274
2024
Q2 		$2.42M Buy
+58,800
New +$2.51M 0.01% 1043

Other funds holding RARE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Point72 Asset Management's RARE Position: Q1 2026 in Review

Point72 Asset Management opened a new position in Ultragenyx Pharmaceutical (RARE) in Q1 2026: 893,295 shares worth $18.7M. The stake represents 0.02% of the portfolio and ranks #834 among its holdings. This is a return to the name: Point72 Asset Management previously reported a position in RARE as recently as Q2 2025.

Point72 Asset Management first reported a position in RARE in Q1 2017 and has held it in 31 quarters since. The position peaked at $67.4M in Q2 2021. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Point72 Asset Management held 893,295 shares of Ultragenyx Pharmaceutical worth $18.7M as of Q1 2026.
  • Ultragenyx Pharmaceutical was a new Point72 Asset Management position in Q1 2026.
  • Ultragenyx Pharmaceutical made up 0.02% of Point72 Asset Management's portfolio in Q1 2026, its #834 holding.
  • Point72 Asset Management first reported a position in Ultragenyx Pharmaceutical in Q1 2017 and has held it in 31 quarters since.
  • Point72 Asset Management's Ultragenyx Pharmaceutical position peaked at $67.4M in Q2 2021.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.